Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model

Kejin Zhou, Liem H. Nguyen, Jason B. Miller, Yunfeng Yan, Petra Kos, Hu Xiong, Lin Li, Jing Hao, Jonathan T. Minnig, Hao Zhu, Daniel J. Siegwart

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

RNA-based cancer therapies are hindered by the lack of delivery vehicles that avoid cancer-induced organ dysfunction, which exacerbates carrier toxicity. We address this issue by reporting modular degradable dendrimers that achieve the required combination of high potency to tumors and low hepatotoxicity to provide a pronounced survival benefit in an aggressive genetic cancer model. More than 1,500 dendrimers were synthesized using sequential, orthogonal reactions where ester degradability was systematically integrated with chemically diversified cores, peripheries, and generations. A lead dendrimer, 5A2-SC8, provided a broad therapeutic window: identified as potent [EC50 <0.02 mg/kg siRNA against FVII (siFVII)] in dose-response experiments, and well tolerated in separate toxicity studies in chronically ill mice bearing MYC-driven tumors (>75 mg/kg dendrimer repeated dosing). Delivery of let-7g microRNA (miRNA) mimic inhibited tumor growth and dramatically extended survival. Efficacy stemmed from a combination of a small RNA with the dendrimer's own negligible toxicity, therefore illuminating an underappreciated complication in treating cancer with RNA-based drugs.

Original languageEnglish (US)
Pages (from-to)520-525
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume113
Issue number3
DOIs
StatePublished - Jan 19 2016

Fingerprint

Dendrimers
Liver Neoplasms
RNA
Neoplasms
Genetic Models
MicroRNAs
Esters
Therapeutics
Growth
Pharmaceutical Preparations

Keywords

  • Cancer
  • Dendrimers
  • MiRNA

ASJC Scopus subject areas

  • General

Cite this

Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model. / Zhou, Kejin; Nguyen, Liem H.; Miller, Jason B.; Yan, Yunfeng; Kos, Petra; Xiong, Hu; Li, Lin; Hao, Jing; Minnig, Jonathan T.; Zhu, Hao; Siegwart, Daniel J.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 113, No. 3, 19.01.2016, p. 520-525.

Research output: Contribution to journalArticle

Zhou, Kejin ; Nguyen, Liem H. ; Miller, Jason B. ; Yan, Yunfeng ; Kos, Petra ; Xiong, Hu ; Li, Lin ; Hao, Jing ; Minnig, Jonathan T. ; Zhu, Hao ; Siegwart, Daniel J. / Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model. In: Proceedings of the National Academy of Sciences of the United States of America. 2016 ; Vol. 113, No. 3. pp. 520-525.
@article{d9489038f1d6435584199e832205282b,
title = "Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model",
abstract = "RNA-based cancer therapies are hindered by the lack of delivery vehicles that avoid cancer-induced organ dysfunction, which exacerbates carrier toxicity. We address this issue by reporting modular degradable dendrimers that achieve the required combination of high potency to tumors and low hepatotoxicity to provide a pronounced survival benefit in an aggressive genetic cancer model. More than 1,500 dendrimers were synthesized using sequential, orthogonal reactions where ester degradability was systematically integrated with chemically diversified cores, peripheries, and generations. A lead dendrimer, 5A2-SC8, provided a broad therapeutic window: identified as potent [EC50 <0.02 mg/kg siRNA against FVII (siFVII)] in dose-response experiments, and well tolerated in separate toxicity studies in chronically ill mice bearing MYC-driven tumors (>75 mg/kg dendrimer repeated dosing). Delivery of let-7g microRNA (miRNA) mimic inhibited tumor growth and dramatically extended survival. Efficacy stemmed from a combination of a small RNA with the dendrimer's own negligible toxicity, therefore illuminating an underappreciated complication in treating cancer with RNA-based drugs.",
keywords = "Cancer, Dendrimers, MiRNA",
author = "Kejin Zhou and Nguyen, {Liem H.} and Miller, {Jason B.} and Yunfeng Yan and Petra Kos and Hu Xiong and Lin Li and Jing Hao and Minnig, {Jonathan T.} and Hao Zhu and Siegwart, {Daniel J.}",
year = "2016",
month = "1",
day = "19",
doi = "10.1073/pnas.1520756113",
language = "English (US)",
volume = "113",
pages = "520--525",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "3",

}

TY - JOUR

T1 - Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model

AU - Zhou, Kejin

AU - Nguyen, Liem H.

AU - Miller, Jason B.

AU - Yan, Yunfeng

AU - Kos, Petra

AU - Xiong, Hu

AU - Li, Lin

AU - Hao, Jing

AU - Minnig, Jonathan T.

AU - Zhu, Hao

AU - Siegwart, Daniel J.

PY - 2016/1/19

Y1 - 2016/1/19

N2 - RNA-based cancer therapies are hindered by the lack of delivery vehicles that avoid cancer-induced organ dysfunction, which exacerbates carrier toxicity. We address this issue by reporting modular degradable dendrimers that achieve the required combination of high potency to tumors and low hepatotoxicity to provide a pronounced survival benefit in an aggressive genetic cancer model. More than 1,500 dendrimers were synthesized using sequential, orthogonal reactions where ester degradability was systematically integrated with chemically diversified cores, peripheries, and generations. A lead dendrimer, 5A2-SC8, provided a broad therapeutic window: identified as potent [EC50 <0.02 mg/kg siRNA against FVII (siFVII)] in dose-response experiments, and well tolerated in separate toxicity studies in chronically ill mice bearing MYC-driven tumors (>75 mg/kg dendrimer repeated dosing). Delivery of let-7g microRNA (miRNA) mimic inhibited tumor growth and dramatically extended survival. Efficacy stemmed from a combination of a small RNA with the dendrimer's own negligible toxicity, therefore illuminating an underappreciated complication in treating cancer with RNA-based drugs.

AB - RNA-based cancer therapies are hindered by the lack of delivery vehicles that avoid cancer-induced organ dysfunction, which exacerbates carrier toxicity. We address this issue by reporting modular degradable dendrimers that achieve the required combination of high potency to tumors and low hepatotoxicity to provide a pronounced survival benefit in an aggressive genetic cancer model. More than 1,500 dendrimers were synthesized using sequential, orthogonal reactions where ester degradability was systematically integrated with chemically diversified cores, peripheries, and generations. A lead dendrimer, 5A2-SC8, provided a broad therapeutic window: identified as potent [EC50 <0.02 mg/kg siRNA against FVII (siFVII)] in dose-response experiments, and well tolerated in separate toxicity studies in chronically ill mice bearing MYC-driven tumors (>75 mg/kg dendrimer repeated dosing). Delivery of let-7g microRNA (miRNA) mimic inhibited tumor growth and dramatically extended survival. Efficacy stemmed from a combination of a small RNA with the dendrimer's own negligible toxicity, therefore illuminating an underappreciated complication in treating cancer with RNA-based drugs.

KW - Cancer

KW - Dendrimers

KW - MiRNA

UR - http://www.scopus.com/inward/record.url?scp=84955317368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955317368&partnerID=8YFLogxK

U2 - 10.1073/pnas.1520756113

DO - 10.1073/pnas.1520756113

M3 - Article

VL - 113

SP - 520

EP - 525

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 3

ER -